SCHEMBL13249136

SCHEMBL13249136

Cc1ccc2c(Br)c3ccccc3c(-c3ccc4ccccc4c3)c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 6/20 0.47
TDP1 Q9NUW8 1/20 0.47
CYP1A2 P05177 6/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
IKBKB O14920 1/20 0.39
MAOA P21397 1/20 0.39
CTRC Q99895 1/20 0.37
GSTP1 P09211 1/20 0.35
ESR1 P03372 1/20 0.35
ESR2 Q92731 1/20 0.35
ALOX5 P09917 2/20 0.35
CYP1A1 P04798 1/20 0.35
CYP1B1 Q16678 1/20 0.35
PDE9A O76083 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29353280 0.92 CYP2A6 (0.55) CYP2A6TDP1CYP1A2ALDH1A1CYP3A4
SCHEMBL365629 0.92 CYP2A6 (0.55) CYP2A6TDP1CYP1A2ALDH1A1CYP3A4
SCHEMBL15056206 0.92 CYP2A6 (0.55) CYP2A6TDP1CYP1A2ALDH1A1CYP3A4
SCHEMBL12968943 0.88 CYP2A6 (0.47) CYP2A6TDP1CYP1A2ALDH1A1CYP3A4
SCHEMBL31347846 0.87 CYP2A6 (0.45) CYP2A6CYP1A2ALDH1A1SMN1; SMN2HSD17B10
SCHEMBL22042806 0.87 CYP2A6 (0.45) CYP2A6CYP1A2ALDH1A1SMN1; SMN2HSD17B10
SCHEMBL169491 0.87 CYP2A6 (0.45) CYP2A6CYP1A2ALDH1A1SMN1; SMN2HSD17B10
SCHEMBL29349874 0.87 CYP2A6 (0.45) CYP2A6CYP1A2ALDH1A1SMN1; SMN2HSD17B10
SCHEMBL30647524 0.85 CYP2A6 (0.43) CYP2A6CYP1A2ALDH1A1SMN1; SMN2HSD17B10
SCHEMBL30100403 0.84 ESR1 (0.43) CYP2A6CYP1A2ALDH1A1SMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8986852-B2 Benzanthracene derivatives for organic electroluminescent devices MERCK PATENT GMBH (DE) 2015-03-24 US disclosed
US-8986852-B2 Benzanthracene derivatives for organic electroluminescent devices MERCK PATENT GMBH (DE) 2015-03-24 US disclosed
US-20100187505-A1 BENZANTHRACENE DERIVATIVES FOR ORGANIC ELECTROLUMINESCENT DEVICES IDEMITSU KOSAN CO., LTD. (JP) 2010-07-29 US disclosed
US-20100187505-A1 BENZANTHRACENE DERIVATIVES FOR ORGANIC ELECTROLUMINESCENT DEVICES IDEMITSU KOSAN CO., LTD. (JP) 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100187505-A1 BENZANTHRACENE DERIVATIVES FOR ORGANIC ELECTROLUMINESCENT DEVICES KCNT1, KCNC1, TMEM109 CYP2A6 2082/4885TDP1 1255/4885CYP1A2 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.